Cannabinoids receptors: popular preclinical target but banned in 137 countries
Pharmaceutical Technology
DECEMBER 5, 2022
Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In Asia, Africa and the Middle East, cannabinoid-based drugs are mostly illegal and continue to present a major regulatory obstacle.
Let's personalize your content